Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Grants to USA and Canada Nonprofits, Institutions, and Researchers for Cancer Research Projects

ELIGIBILITY:

Geographic Focus

USA: AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew York CityNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashington, DCWashingtonWest VirginiaWisconsinWyoming

Canada: AlbertaBritish ColumbiaManitobaNew BrunswickNewfoundland and LabradorNorthwest TerritoriesNova ScotiaNunavutOntarioPrince Edward IslandQuebecSaskatchewanYukon

GrantRegions Object ( [regions] => Array ( ) [is_initialized] => [error_messages] => Array ( ) [qm] => QueryManager Object ( [is_debug] => [conn] => mysqli Object ( [affected_rows] => 0 [client_info] => mysqlnd 5.0.12-dev - 20150407 - $Id: 3591daad22de08524295e1bd073aceeff11e6579 $ [client_version] => 50012 [connect_errno] => 0 [connect_error] => [errno] => 0 [error] => [error_list] => Array ( ) [field_count] => 2 [host_info] => 172.16.38.157 via TCP/IP [info] => [insert_id] => 0 [server_info] => 5.5.5-10.5.18-MariaDB [server_version] => 100518 [stat] => Uptime: 2771462 Threads: 268 Questions: 468519618 Slow queries: 1098 Opens: 106756 Open tables: 2239 Queries per second avg: 169.051 [sqlstate] => 00000 [protocol_version] => 10 [thread_id] => 75817593 [warning_count] => 0 ) ) [has_regions] => 1 [state_names] => Array ( [0] => Alabama; [1] => Alaska; [2] => Arizona; [3] => Arkansas; [4] => California; [5] => Colorado; [6] => Connecticut; [7] => Delaware; [8] => Florida; [9] => Georgia; [10] => Hawaii; [11] => Idaho; [12] => Illinois; [13] => Indiana; [14] => Iowa; [15] => Kansas; [16] => Kentucky; [17] => Louisiana; [18] => Maine; [19] => Maryland; [20] => Massachusetts; [21] => Michigan; [22] => Minnesota; [23] => Mississippi; [24] => Missouri; [25] => Montana; [26] => Nebraska; [27] => Nevada; [28] => New Hampshire; [29] => New Jersey; [30] => New Mexico; [31] => New York; [32] => North Carolina; [33] => North Dakota; [34] => New York City; [35] => Ohio; [36] => Oklahoma; [37] => Oregon; [38] => Pennsylvania; [39] => Rhode Island; [40] => South Carolina; [41] => South Dakota; [42] => Tennessee; [43] => Texas; [44] => Utah; [45] => Vermont; [46] => Virginia; [47] => Washington; [48] => Washington, DC; [49] => West Virginia; [50] => Wisconsin; [51] => Wyoming; ) [province_names] => Array ( [0] => Alberta; [1] => British Columbia; [2] => Manitoba; [3] => New Brunswick; [4] => Newfoundland and Labrador; [5] => Northwest Territories; [6] => Nova Scotia; [7] => Nunavut; [8] => Ontario; [9] => Prince Edward Island; [10] => Quebec; [11] => Saskatchewan; [12] => Yukon; ) [country_names] => Array ( ) [is_israel] => [territories] => Array ( ) [free_associations] => Array ( ) )

RUNX1 Early Career Investigator Grant

Alex's Lemonade Stand Foundation (ALSF) and RUNX1 Research Program (RRP)


Agency: Foundation

GrantWatch ID #187469

Grant Description

Grants of up to $60,000 to USA and Canada nonprofit institutions, organizations, and researchers for cancer research projects. Funding is intended to support early-career scientists focused on a medical area that has historically received limited researcher attention. Specifically, funding may be used to research strategies that may lead to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with RUNX1-FPD.

A research and advocacy venture committed to funding world-class, innovative, and cross-disciplinary cancer research to develop a cancer prevention therapy for RUNX1 familial platelet disorder (RUNX1-FPD) with predisposition to blood cancer. The program also aims to support, inform, educate, and connect patients, healthcare providers, researchers, and other stakeholders in the RUNX1 community.

Aims of research proposals must be relevant to the goal of preventing hematologic malignant transformation in RUNX1-FPD. Proposals that seek to translate from bench to bedside will receive priority. 

Example areas of research interests include:

  • Characterize the role of RUNX1 in DNA damage repair and the impact germline RUNX1 mutations may have on acquisition of somatic mutations in the blood.
  • Determine the functional differences of human RUNX1 mutant proteins and their role in conferring risk of hematologic malignancies.
  • Define the effects of germline RUNX1 mutations on specific immune cells, especially T and B cells, and the potential contribution to clonal evolution to HM
  • Identify druggable mechanisms, with a focus on drug repurposing, that drive clonal hematopoiesis, clonal expansion, and ultimately malignant transformation in RUNX1-FPD patients.
  • Develop drug screening programs aimed at raising normal RUNX1 activity to improve hematopoietic function and reduce HM risk.
  • Investigate feasibility of targeting RNA splicing for disease therapy in patients with splice-site mutations.
  • Investigate potential for mRNA vaccine for RUNX1-FPD hematologic malignancy prevention.

Need help writing this grant?

Eligibility:

  • Others (see text field entitled "Additional Eligibility Criteria" for clarification)

Additional Eligibility Criteria:

- Applicant institutions must be based in the United States or Canada. Applicants need not be United States citizens. Funds must be granted to nonprofit institutions or organizations.
- Applicants must have an MD, PhD, or MD/PhD (DO, MBBS or equivalent) and be within five years of their first faculty appointment as an Assistant Professor or equivalent tenure-track position. Associate and Full Professors are ineligible. If at the Instructor level, the applicant must submit a letter of support from their mentor at the sponsoring institution.
- A minimum of 75% of the applicant’s time during the award period must be allocated as protected time for all research activities. This percentage of time includes both activities on this grant and the applicant’s other research responsibilities.
- Applicants may have research grants from other funding sources during the award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap.
- Applicants must have research experience working in and a deep understanding of normal or malignant hematopoiesis and/or immunology.
- One resubmission of a previously unfunded application is allowed. Use the Resubmission section of the application to respond to the prior RRP/ALSF critique of the proposal. The response will be scored in the review process in addition to the criteria used for new applications. Resubmissions compete with new applicants for funding.

Restrictions:
- The RUNX1 Early Career Grant is not transferable to another investigator.
- RRP/ALSF does not fund proposals for research utilizing human embryonic stem cells or non-human primates. Research with human induced pluripotent stem cells is permissible.

Pre-Application Information:

Timeline:
- Application Deadline: December 21, 2022 (8:00 PM ET)
- Award Notification Date: February, 2023
- Project Start Date: April 2023 (contingent upon receipt and approval of new award requirements)
- Project End Date: April 2026
- Progress Reports: Interim, 6-month check-in based on project start date
- Final Report: Two months after project end date
- RPP Scientific Meeting: Annual

Additional Funding Information:

Estimated Size of Grant:

A maximum of $60,000 in total costs may be requested per year.

Term of Contract:

The RUNX1 Early Career Investigator grant is a 3-year award.
- Project Start Date: April 2023 (contingent upon receipt and approval of new award requirements)
- Project End Date: April 2026

Contact Information:

Apply online: https://alsfapps.force.com/FGM_Portal__CommunitySignin

If you have any questions regarding your eligibility or your research proposal topic, the Foundation encourages you to reach out to Katrin Ericson, Executive Director at RRP at kericson@runx1-fpd.org.

All other questions can be submitted to Margaret Poore at M.Poore@AlexsLemonade.org.

Alex’s Lemonade Stand Foundation for Childhood Cancer
333 E. Lancaster Ave, #414
Wynnewood, PA 19096 USA
Phone: 866.333.1213

Live Chat Chat Now